Please login to the form below
Cometriq
This page shows the latest Cometriq news and features for those working in and with pharma, biotech and healthcare.
Exelixis bounces back with new prostate cancer data
Cabozantinib, a c-MET and VEGFR2 inhibitor, is already approved under the brand name Cometriq as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe.
Latest news
-
HIV prevention pill heads July CHMP recommendations
Cabozantinib was approved for this indication under the Cometriq brand name in late 2013, while lenvatinib got the nod last year as Lenvima.
-
Exelixis axes staff as lead cancer programme fails
Cabozantinib - which acts as a c-MET and VEGFR2 inhibitor - is already approved as Cometriq for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the US and Europe, but
-
Cancer Drugs Fund adds Roche, Celgene and Exelixis drugs
Avastin, Abraxane and Cometriq will be funded in certain indications. Three new drugs have been added to the Cancer Drugs Fund (CDF) in a move NHS England says could benefit 900 ... The Fund will add new NHS coverage in England for Roche's Avastin
-
Roche drug fails in lung cancer trial
One c-MET inhibitor has reached the market - Exelixis' Cometriq (cabozantinib) for thyroid cancer - although this has a dual activity and also inhibits VEGFR2.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2016
Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
